Replies to post #3932 on GTC Biotherapeutics (fka GTCB)

[microcapfun]

In any case, the main point is that $240M per year is not a trivial revenue stream for an FoB maker to pursue—provided that the FoB is substitutable for the original drug and doesn’t have to be actively marketed.


Point taken.

micro